3′-deoxy-3′-18F-fluorothymidine (FLT) Positron Emission Tomography for Early Prediction of Response to Chemoradiotherapy - A Clinical Application Model of Esophageal Cancer

Seminars in Oncology

Volumn 34, Issue SUPPL. 1, 2007, Pages

  Chao, K S Clifford ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

3' FLUOROTHYMIDINE; 3' FLUOROTHYMIDINE F 18; DOCETAXEL; FLUORINE 18; FLUORODEOXYGLUCOSE F 18; KI 67 ANTIGEN; UNCLASSIFIED DRUG; 2',3' DIDEOXYNUCLEOSIDE DERIVATIVE; ANTINEOPLASTIC AGENT; DIAGNOSTIC AGENT; FLUORINE; TAXOID;

ARTICLE; CANCER CHEMOTHERAPY; CANCER MODEL; CANCER RADIOTHERAPY; DIAGNOSTIC ACCURACY; ESOPHAGUS CANCER; HUMAN; NONHUMAN; POSITRON EMISSION TOMOGRAPHY; PREDICTION; PRIORITY JOURNAL; TREATMENT RESPONSE; TUMOR GROWTH; TUMOR VOLUME; TUMOR XENOGRAFT; ADJUVANT THERAPY; ANIMAL; CELL PROLIFERATION; DISEASE MODEL; ESOPHAGUS TUMOR; FORECASTING; MINIMAL RESIDUAL DISEASE; MOUSE; REMISSION; SCINTISCANNING; TREATMENT OUTCOME; TUMOR CELL LINE;

ANIMALS; ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; CELL PROLIFERATION; DIDEOXYNUCLEOSIDES; DISEASE MODELS, ANIMAL; ESOPHAGEAL NEOPLASMS; FLUORINE RADIOISOTOPES; FLUORODEOXYGLUCOSE F18; FORECASTING; HUMANS; MICE; NEOADJUVANT THERAPY; NEOPLASM, RESIDUAL; POSITRON-EMISSION TOMOGRAPHY; RADIOTHERAPY, ADJUVANT; REMISSION INDUCTION; TAXOIDS; TREATMENT OUTCOME;

EID: 34247113733     PISSN: 00937754     EISSN: None     Source Type: Journal    
DOI: 10.1053/j.seminoncol.2007.01.002     Document Type: Article

References (20)

1. Swisher S.G., Erasmus J., Maish M., et al. 2-fluoro-2-deoxy-D-glucose positron emission tomography imaging is predictive of pathologic response and survival after preoperative chemoradiation in patients with esophageal carcinoma. Cancer 101 (2004) 1776-1785
2. Berger A.C., Farma J., Scott W.J., et al. Complete response to neoadjuvant chemoradiotherapy in esophageal carcinoma is associated with significantly improved survival. J Clin Oncol 23 (2005) 4330-4337
3. Weber W.A., Ott K., Becker K., et al. Prediction of response to preoperative chemotherapy in adenocarcinoma of the esophagogastric junction by metabolic imaging. J Clin Oncol 19 (2001) 3058-3065
4. Wieder H.A., Brucher B.L., Zimmerman F., et al. Time course of tumor metabolic activity during chemoradiotherapy of esophageal squamous cell carcinoma and response to treatment. J Clin Oncol 22 (2004) 900-908
5. 3H-fluorothymidine using preclinical tumor models. Clin Cancer Res 12 (2006) 4590-4597
6. Arslan N., Miller T.R., Dehdashti F., et al. Evaluation of response to neoadjuvant therapy by quantitative 2-deoxy-2-[18f]fluoro-D-glucose with positron emission tomography in patients with esophageal cancer. Mol Imaging Biol 4 (2002) 301-310
7. Kubota R., Yamada S., Kubota K., et al. Intratumoral distribution of fluorine-18-fluorodeoxyglucose in vivo: High accumulation in macrophages and granulation tissues studied by microautoradiography. J Nucl Med 33 (1992) 1972-1980
8. Nakamura R., Obara T., Katsuragawa S., et al. Failure in presumption of residual disease by quantification of FDG uptake in esophageal squamous cell carcinoma immediately after radiotherapy. Radiat Med 20 (2002) 181-186
9. van Westreenen H.L., Heeren P.A.M., Jager P.L., et al. Pitfalls of positive findings in staging esophageal cancer with F-18-fluorodeoxyglucose positron emission tomography. Ann Surg Oncol 10 (2003) 1100-1105
10. Barthel H., Cleij M.C., Collingridge D.R., et al. 3′deoxy-3′-[18F]fluorthymidine as a new marker for monitoring tumor response to antiproliferative therapy in vivo with positron emission tomography. Cancer Res 63 (2003) 3791-3798
11. Leyton J., Latigo J.R., Perumal M., et al. Early detection of tumor response to chemotherapy by 3′-deoxy-3′-[18f]fluorothymidine positron emission tomography: The effect of cisplatin on a fibrosarcoma tumor model in vivo. Cancer Res 65 (2005) 4202-4210
12. Waldherr C., Mellinghoff I.K., Tran C., et al. Monitoring antiproliferative responses to kinase inhibitor therapy in mice with 3′-deoxy-3′-18F-fluorothymidine PET. J Nucl Med 46 (2005) 114-120
13. 18F-FDG for differentiating tumor from inflammation in a rodent model. J Nucl Med 45 (2004) 695-700
14. 18F-FDG. J Nucl Med 44 (2003) 1426-1431
15. Francis D.L., Freeman A., Visvikis D., et al. In vivo imaging of cellular proliferation in colorectal cancer using positron emission tomography. Gut 52 (2003) 1602-1606
16. Wagner M., Seitz U., Buck A., et al. 3′-[18F]fluoro-3′-deoxythymidine ([18F]-FLT) as positron emission tomography tracer for imaging proliferation in a murine B-cell lymphoma model and in the human disease. Cancer Res 63 (2003) 2681-2687
17. Vesselle H., Grierson J., Muzi M., et al. In vivo validation of 3′-deoxy-3′-[(18)F]fluorothymidine ([(18F)FLT] as a proliferation imaging tracer in humans: Correlation of [(18)F]FLT uptake by positron emission tomography with Ki-67 immunohistochemistry and flow cytometry in human lung tumors. Clin Cancer Res 8 (2002) 3315-3323
18. Cobben D.C., Elsinga P.H., Suurmeijer A.J., et al. Detection and grading of soft tissue sarcomas of the extremities with (18)F-3′-fluoro-3′-deoxy-L-thymidine. Clin Cancer Res 10 (2004) 1685-1690
19. Apisarnthanarax S., and Chao K.S.C. Current imaging paradigms in radiation oncology. Radiat Res 163 (2005) 1-25
20. 18F-FDG PET in esophageal cancer. J Nucl Med 46 (2005) 400-404